Special Lunch Symposia

ANR2018 Special Lunch Symposia

Please find information below on the Special Lunch Symposia that have been confirmed to-date for ANR2018. This information will be updated as the conference nears.

Registration to both symposia are free. Please note that lunch will be provided to the first 100 fully paid ANR Meeting registrants. To attend, please indicate when registering. 

Anti-GD2 Therapy for Neuroblastoma: Present and Future


Wednesday May 9, 2018, 11:30AM-1:00 PM

Chair:
Paul Sondel, MD (University of Wisconsin, USA)

Speakers:
– Holger Lode, MD, PhD (University of Greifswald, Germany)
Julie Park, MD (University of Washington, USA)
Alice Yu, MD PhD (University of California, USA)
Paul Sondel, MD (University of Wisconsin, USA)

Strategies For Improving Neuroblastoma Outcome Using Anti-GD2 Immunotherapy

Julie Park will summarize recent data from COG studies that have combined anti-GD2 mAb with chemotherapy and present the COG approach for moving forward with testing of anti-GD2 + chemotherapy in the setting of relapsed/refractory disease as well as newly diagnosed high-risk neuroblastoma.

Efficacy and Perspectives of Anti-GD2 Therapy

Holger Lode will discuss ongoing clinical results using long-term-infusion of anti-GD2 mAb to avoid toxicity, associations of response with KIR and FcR genotype, development of vaccine approaches with an anti-idiotypic mAb (Ganglidiomab) and preclinical development with anti-GD2 mAb in combination with PD1 checkpoint blockade.

Identifying Predictive Immunological Biomarkers and Immuno-Oncology Combination to Improve Outcome of Anti-GD2 Therapy

Alice Yu will present recent correlative biology/immunology analyses for patients receiving the COG anti-GD2 + cytokine regimen, preclinical data pursuing other cytokine approaches, and potential applications for anti-GD2 treatment in other diseases.

Activation of Innate and Adaptive Immunity with Anti-GD2 and IL2

Paul Sondel will address KIR/KIR-ligand genotypes that are most associated with benefit from immunotherapy and preclinical ways anti-GD2 antibody plus cytokines and radiotherapy are allowing localized tumors to function as in situ vaccines.

Supported through an unrestricted medical education grant by United Therapeutics Oncology

Neuroblastoma: Innovations on The Horizon


Saturday, May 12, 2018, 12:00-1:30 PM

Chair:
Sara Federico, MD (St. Jude Children’s Research Hospital, USA)

Speakers:
John Anderson, PhD (UCL Great Ormond Street Institute of Child Health, UK)
Juliet Gray, MA, MB, BS, MRCPCH, PhD (University of Southampton, UK)
Daniel Morgenstern, MB, BChir, PhD, FRCPCH (Hospital for Sick Children, Canada)

Neuroblastoma—A Current State of Affairs and Remaining Needs

Dr. Daniel Morgenstern will deliver a brief discussion of the current state of affairs in high-risk neuroblastoma, including a review of its epidemiology and global burden, and the current information on risk stratification and prognosis.

Therapeutic Considerations for Patients with High-Risk Neuroblastoma

Dr. Morgenstern will then describe the current treatment paradigms for high-risk neuroblastoma, differentiating between therapeutic regimens for relapsed/refractory neuroblastoma in North America and Europe, with a brief review of treatment-related late effects.

Anti-GD2 Approaches

Dr. Juliet Gray will describe the therapeutic rationale of the use of anti-GD2 antibodies in the treatment of high-risk neuroblastoma, including a review of the products currently in development or seeking approval; dinutuximab and dinutuximab beta, and the European experience with the use of dinutuximab and dinutuximab beta, as well as humanized 3F8 and hu14.18K322A, which are investigational agents being evaluated in clinical trials or available through managed/expanded access programs. 

Opportunities with New and Emerging Immunotherapies

Dr. John Anderson will then give an overview about the opportunities for new and emerging immunotherapeutic approaches to the prognosis and treatment of neuroblastoma. This will include a review of evidence suggesting that neuroblastoma is a “cold” tumor type, and opportunities with synthetic immunotherapies (eg, CAR-T [including ALK CAR], antibodies, and bispecific antibodies) in combination with novel target immune checkpoint inhibitors or other small-molecule inhibitors.

Q&A Session and Panel Discussion: Future Outlook for Patients with High-Risk Neuroblastoma

Dr. Sara Federico will conclude the symposium with a panel discussion about timely research and clinical developments of relevance and interest to the attendees, such as treatments beyond immunotherapy (BCL-2 inhibition, aurora-A kinase inhibition, targeted radiotherapy [MIBG]), a discussion of various immunotherapeutic approaches to improve patient experiences and outcomes, and the use of combination therapy.

Supported by EUSA Pharma (UK) Ltd

Want to Learn More About Registration?

Click here